Very true it's a different mechanism. But elotuzumab is pushing response rates extremely high. There's also carfilzomib, oral velcade, oral carfilzomib, pomalidomide. There's also perifosene if you believe in that one. The opportunity in relapsed refractory is going to get smaller and smaller and harder to develop. I see little chance of 520 moving up front and displacing well established drugs and mechanisms. At this point I find 520 in MM to be of marginal promise.
Market Data 
Markets 
AI
